Fujian Haixi Pharma says China NMPA clears HXP089 IND for glioblastoma trial

PUBT · 1d ago
Fujian Haixi Pharma says China NMPA clears HXP089 IND for glioblastoma trial
  • Fujian Haixi Pharmaceuticals secured NMPA clearance for an IND for HXP089 in glioblastoma, enabling clinical trials in China.
  • HXP089 is a multi-target small-molecule designed to penetrate the blood-brain barrier; the program moves from preclinical into clinical development.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fujian Haixi Pharmaceuticals Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260714-12243571), on July 14, 2026, and is solely responsible for the information contained therein.